Synchronous Virtual Event on 

Sunday, May 19, 2024

Join Dr. Marc Bloomenstein and Dr. Doug Devries over your morning coffee for a riveting three-hour escapade, brimming with the latest breaking news to elevate your practice! 

Our engaging duo gives you the inside scoop on integrating the freshest eye care innovations into your daily grind, while also demystifying the art of patient conversation. 

Prepare for an invigorating blend of hands-on advice and sparkling repartee, all designed to spice up your routine and spark inspiration. Here's to making eye care exhilarating! 

This activity, COPE Activity Number 128301, is accredited by COPE for continuing education for optometrists.

Course 91103-TD: 1.0 credit

Course 91104-TD: 1.0 credit

Course 91105-TD: 1.0 credit

Synchronous Virtual Event on 

Sunday, May 19, 2024

8:00am - 11:00am PST

Agenda

8:00 AM

Introduction

Case 1: Dry Eye Syndrome in a Middle-Aged Adult

Case 2 : Meibomian Gland Dysfunction (Mild Case)

Audience Q&A

Case 3: Early Signs of Demodex Blepharitis

Case 4: Managing Sjogren’s Syndrome with Concurrent Dry Eye

Case 5: Thyroid Eye Disease Leading to Complex Ocular Surface Issues

Audience Q&A

Case 6: Neurotrophic Keratitis Complicated by Diabetes

Case 7: Severe Keratoconus with Contact Lens Intolerance

Case 8: Complex Case Involving Multiple Ocular Surface Issues

Audience Q&A

Conclusion

8:10 AM

8:35 AM

8:55 AM

9:00 AM

9:20 AM

9:40 AM

9:55 AM

10:00 AM

10:30 AM

10:50 AM

10:55 AM

11:00 AM

Upon completion of this activity, the participant should be able to:

A. Describe specific steps to apply new and emerging therapeutic options and protocols to various types of patients with ocular surface issues.

B. Outline best practices for educating ocular surface patients, setting expectations, and guiding them throughout their journey.

This activity, COPE Activity Number 128301, is accredited by COPE for continuing education for optometrists.

Course 91103-TD: 1.0 credit

Course 91104-TD: 1.0 credit

Course 91105-TD: 1.0 credit

Grant Support Statement

This activity is supported by an unrestricted educational grant from Alcon, Dompé, Harrow, Horizon Therapeutics, OCuSOFT, Sight Sciences, Tarsus Pharmaceuticals, Inc. and Trukera.  

Disclosures

Marc Bloomenstein, OD, FAAO, Planner & Faculty Member, has the following relevant financial relationships: Consultant & Speaker: AbbVie, Bausch + Lomb, Johnson & Johnson Vision, Sight Sciences, Sun Pharma and Viatris. The following financial relationships ended in 2022: Consultant: Avagen, Bruder, Iveric, Ocuphire, OcuSoft, Riechert, Tarsus, Thea, TopCon, TruKera, and Visus. Consultant & Speaker: Dompe and Kala. Speaker: Alcon and EyeVance.

Douglas K. Devries, OD, Planner & Faculty Member, has the following relevant financial relationships: Consultant: Aescult, Akorn, Alcon, Alydera, Avelino, Azura, Bruder, Novartis, OcuSoft, Oyster Point, Quidel, TearLab, Thea, TruKera, and Visus. Consultant & Speaker: Alcon, Bausch + Lomb, BelphEx, EyeVance, Johnson & Johnson Vision, Kala, Science Based Health, Sight Sciences, Sun Pharma, and Tarsus. Stock Options/Private Company: RPS. Dr. Devries has also disclosed the following non-relevant financial relationships: Consultant & Speaker: Lumenis. Partner: Ophthalmic Resources (no product available).  

Copyright © 2024 The Fundingsland Group. All rights reserved.